CN108431026B - 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 - Google Patents

制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 Download PDF

Info

Publication number
CN108431026B
CN108431026B CN201680077178.3A CN201680077178A CN108431026B CN 108431026 B CN108431026 B CN 108431026B CN 201680077178 A CN201680077178 A CN 201680077178A CN 108431026 B CN108431026 B CN 108431026B
Authority
CN
China
Prior art keywords
fucose
host cell
protein
gmd
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680077178.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108431026A (zh
Inventor
S·米萨吉
J·B·洛
B·R·斯内德克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202310074105.0A priority Critical patent/CN116731147A/zh
Publication of CN108431026A publication Critical patent/CN108431026A/zh
Application granted granted Critical
Publication of CN108431026B publication Critical patent/CN108431026B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680077178.3A 2015-11-02 2016-11-01 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 Active CN108431026B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310074105.0A CN116731147A (zh) 2015-11-02 2016-11-01 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562249828P 2015-11-02 2015-11-02
US62/249,828 2015-11-02
US201662338280P 2016-05-18 2016-05-18
US62/338,280 2016-05-18
PCT/US2016/059922 WO2017079165A1 (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310074105.0A Division CN116731147A (zh) 2015-11-02 2016-11-01 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Publications (2)

Publication Number Publication Date
CN108431026A CN108431026A (zh) 2018-08-21
CN108431026B true CN108431026B (zh) 2023-02-17

Family

ID=57326491

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680077178.3A Active CN108431026B (zh) 2015-11-02 2016-11-01 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
CN202310074105.0A Pending CN116731147A (zh) 2015-11-02 2016-11-01 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310074105.0A Pending CN116731147A (zh) 2015-11-02 2016-11-01 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Country Status (14)

Country Link
US (3) US10975168B2 (enExample)
EP (2) EP3925970A1 (enExample)
JP (1) JP6983772B2 (enExample)
KR (2) KR20250051156A (enExample)
CN (2) CN108431026B (enExample)
AU (2) AU2016350732A1 (enExample)
BR (1) BR112018007356A2 (enExample)
CA (1) CA2999047A1 (enExample)
ES (1) ES2875274T3 (enExample)
IL (1) IL258161B2 (enExample)
MX (1) MX2018004831A (enExample)
PL (1) PL3371206T3 (enExample)
SG (2) SG11201802773RA (enExample)
WO (1) WO2017079165A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
CA3010598A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
EP3775251A1 (en) * 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
EP3802610A1 (en) 2018-06-05 2021-04-14 Amgen Inc. Modulating antibody dependent cellular phagocytosis
CA3110254C (en) * 2018-08-29 2023-08-29 United Biopharma Inc Afucosylated antibodies and manufacture thereof
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
BR112021018608A2 (pt) 2019-03-20 2021-11-23 Univ California Anticorpos para claudina-6 e conjugados de fármaco
EP3941944A4 (en) 2019-03-20 2022-11-30 The Regents of the University of California Claudin-6 bispecific antibodies
MX2021013628A (es) 2019-05-06 2022-03-07 Amgen Inc Modulación de las funciones efectoras de anticuerpos.
CA3152547A1 (en) * 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
US20240092935A1 (en) * 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
MX2022015948A (es) * 2020-07-02 2023-04-05 Gigagen Inc Proteínas de unión anti-ctla-4 y métodos de uso de estas.
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4380619A4 (en) * 2021-08-06 2025-07-30 Anyadi Llc PROCESS FOR PRODUCING PERSONALIZED CANCER IMMUNOTHERAPY
KR102890992B1 (ko) * 2023-01-26 2025-12-02 팔라디바이오텍 주식회사 물질의 세포막 파괴 활성을 확인하는데 사용하기 위한 조성물, 및 그의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459603A (zh) * 2009-06-02 2012-05-16 瑞泽恩制药公司 岩藻糖基化缺陷型细胞

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
EP1117815A1 (en) 1998-09-29 2001-07-25 Pioneer Hi-Bred International Inc. Mar/sar elements flanking rsyn7-driven construct
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
SG141239A1 (en) 2001-01-26 2008-04-28 Selexis Sa Matrix attachment regions and methods for use thereof
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
EP1888638A2 (en) * 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
WO2007011041A1 (ja) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物
PE20080980A1 (es) * 2006-10-12 2008-09-02 Genentech Inc Anticuerpos anti-linfotoxina alfa
CA2763164A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
AU2012226398B9 (en) * 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
WO2015026846A1 (en) * 2013-08-19 2015-02-26 Biogen Idec Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
WO2016075662A2 (en) * 2014-11-15 2016-05-19 Zumutor Biologics, Inc. Dna-binding domain, non-fucosylated and partially fucosylated proteins, and methods thereof
US11267899B2 (en) * 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459603A (zh) * 2009-06-02 2012-05-16 瑞泽恩制药公司 岩藻糖基化缺陷型细胞

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cell lines expressing mutant FX proteins to generate proteins with reduced rate of fucosylation: WO2010141478;Taupin p;《expert opin ther pat》;20110731;第21卷(第7期);1143-1146 *
Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus;Smith pl等;《j cell biol》;20020819;第158卷(第4期);801-815 *
Double knockdown of alpha 1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC;Imai-nishiya h等;《BMC biotechnol》;20071130;第7卷(第84期);1-13 *
Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics;kanda y等;《journal of biotechnology》;20070506;第130卷(第3期);300-310 *

Also Published As

Publication number Publication date
ES2875274T3 (es) 2021-11-10
IL258161B2 (en) 2023-08-01
AU2016350732A1 (en) 2018-04-05
CA2999047A1 (en) 2017-05-11
US20180251572A1 (en) 2018-09-06
EP3371206A1 (en) 2018-09-12
SG11201802773RA (en) 2018-05-30
KR102793554B1 (ko) 2025-04-14
BR112018007356A2 (pt) 2018-10-23
KR20180068967A (ko) 2018-06-22
US20210214462A1 (en) 2021-07-15
KR20250051156A (ko) 2025-04-16
IL258161A (en) 2018-05-31
JP2019505164A (ja) 2019-02-28
EP3371206B1 (en) 2021-04-14
AU2022202460A1 (en) 2022-05-05
IL258161B1 (en) 2023-04-01
US10975168B2 (en) 2021-04-13
CN108431026A (zh) 2018-08-21
CN116731147A (zh) 2023-09-12
EP3925970A1 (en) 2021-12-22
US11802165B2 (en) 2023-10-31
SG10202103875WA (en) 2021-06-29
US20240158536A1 (en) 2024-05-16
PL3371206T3 (pl) 2021-09-27
US12391769B2 (en) 2025-08-19
WO2017079165A1 (en) 2017-05-11
JP6983772B2 (ja) 2021-12-17
MX2018004831A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
US12391769B2 (en) Methods of making fucosylated and afucosylated forms of a protein
US20230203169A1 (en) Recombinant antibody having unique glycan profile produced by cho host cell with edited genome and preparation method thereof
KR101275452B1 (ko) 글리코실화된 항체
JP2022058603A (ja) Ｆｃ含有タンパク質の発現
CN101460522B (zh) 糖基化抗体
WO2025226354A1 (en) Engineered glycoprotein population and uses thereof
HK1129684A (en) Glycosylated antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259370

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant